[ad_1]
The United Kingdom became the first country to authorize the distribution of a product with simpler logistics than others developed so far.
The government said the Medicines and Health Products Agency (MHRA) had given permission to distribute a vaccine developed by the University of Oxford and the British pharmaceutical company AstraZeneca in case of emergency.
Pascal Soriot, CEO of AstraZeneca, said that “today is an important day for millions of people in the UK to gain access to this new vaccine. It has been shown to be effective, well tolerated, and is generally administered and supplied. AstraZeneca supplies it without making any profit. “
“We would like to thank our many colleagues from AstraZeneca |, the University of Oxford, the UK government and tens of thousands of clinical trial participants,” he added.
The University of Oxford and the pharmaceutical company AstraZeneca applied to the UK Medicines Authority for authorization to distribute their vaccine against the COVID-19 coronavirus infection on December 23.
The majority of the UK population is expected to be vaccinated with AstraZeneca and the University of Oxford, a government that ordered 100 million. dose.
A study published in the medical journal The Lancet in early December confirms that the vaccine is effective by an average of 70%. cases. In patients who received two full doses of the vaccine, the effectiveness was 62 percent, while the effectiveness increased to 90 percent in the first half and in the second full dose.
The biggest difference from the Pfizer vaccine is that the vaccine developed by the University of Oxford does not need to be stored at extremely low temperatures.
Like most vaccines, it should be transported to vaccination centers in special freezers or refrigerated containers, chilled between 2 and 8 degrees Celsius and protected from light.
It is said to be the cheapest vaccine against COVID so far and its price is equivalent to a “cup of coffee.” Sky News reports it will cost no more than £ 3 per dose (it will take a dose and a half or two to gain immunity).
A coronavirus vaccine developed by Pfizer and BioNTech is already being vaccinated in the UK. According to the developers, the effectiveness of this vaccine is 95%. Several people received their second and final dose of the coronavirus vaccine on Tuesday.
Europe will have to wait
The European Medicines Agency (EMA) is unlikely to recommend the use of AstraZeneca’s COVID-19 vaccine in January, according to the agency’s Deputy Executive Director Noel Wathion, Belgian newspaper Het Nieuwsblad said on Tuesday.
“Currently AstraZeneca has only provided information on clinical trials to the European Medicines Agency. We need more data on the quality of its vaccine,” said Wathion.
Additionally, AstraZeneca has not yet submitted the required formal application to recommend the use of the vaccine.
The University of Oxford and pharmaceutical company AstraZeneca last week applied to the UK Medicines Authority for permission to distribute their COVID-19 vaccine.
AstraZeneca was the first pharmaceutical company to sign a contract with the European Commission for 300 million. COVID-19 vaccine dose with the possibility of selling another 100 million units to the unit. dose.
The vaccine is currently being vaccinated in the Community by Pfizer and BioNTech, which have been approved by the European Commission following the positive EVA recommendations. A meeting is scheduled for January 6, during which the EVA will decide on the authorization of the Moderna vaccine against COVID-19.
It is strictly prohibited to use the information published by DELFI on other websites, in the media or elsewhere, or to distribute our material in any way without consent, and if consent has been obtained, it is necessary to indicate DELFI as the source.
[ad_2]
